• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

调节性 T 细胞对肝细胞癌预后影响的系统评价和荟萃分析方案。

Impact of regulatory T cells on the prognosis of hepatocellular carcinoma: A protocol for systematic review and meta analysis.

机构信息

Department of Medical Laboratory, Yancheng No.1 People's Hospital & Yancheng First Hospital Affiliated Hospital of Nanjing University Medical School.

College of Medical Technology, Jiangsu Vocational College of Medicine, Yancheng, P.R. China.

出版信息

Medicine (Baltimore). 2021 Jan 22;100(3):e23957. doi: 10.1097/MD.0000000000023957.

DOI:10.1097/MD.0000000000023957
PMID:33545975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7837976/
Abstract

BACKGROUND

This meta-analysis aimed to systematically review current available literature to assess the impact of regulatory T cells (Tregs) on the prognosis of hepatocellular carcinoma (HCC).

METHODS

We will browse the online databases of PubMed and Cochrane Library. The summary hazard ratio (HR) and their 95% confidence intervals (CIs) will be combined to present the value reported in the study.

CONCLUSION

Our meta-analysis will provide useful guidance in treatment of HCC based on the reported evidences regarding the impact of Tregs on the prognosis of HCC.

OSF REGISTRATION NUMBER

10.17605/OSF.IO/3Q8PW.

摘要

背景

本荟萃分析旨在系统地回顾现有文献，评估调节性 T 细胞（Tregs）对肝细胞癌（HCC）预后的影响。

方法

我们将检索 PubMed 和 Cochrane Library 的在线数据库。将汇总的风险比（HR）及其 95%置信区间（CI）合并，以呈现研究报告中的数值。

结论

我们的荟萃分析将基于 Tregs 对 HCC 预后影响的报告证据，为 HCC 的治疗提供有用的指导。

OSF 注册号：10.17605/OSF.IO/3Q8PW。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9701/7837976/988e347b7455/medi-100-e23957-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9701/7837976/988e347b7455/medi-100-e23957-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9701/7837976/988e347b7455/medi-100-e23957-g001.jpg

相似文献

1
Impact of regulatory T cells on the prognosis of hepatocellular carcinoma: A protocol for systematic review and meta analysis.调节性 T 细胞对肝细胞癌预后影响的系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 Jan 22;100(3):e23957. doi: 10.1097/MD.0000000000023957.
2
Diagnostic performance of blood-based liquid biopsies in hepatocellular carcinoma: A protocol for systematic review and meta-analysis.基于血液的液体活检在肝细胞癌中的诊断性能：系统评价与荟萃分析方案
Medicine (Baltimore). 2020 Oct 9;99(41):e22594. doi: 10.1097/MD.0000000000022594.
3
Liver stiffness measured by magnetic resonance elastography in early recurrence of hepatocellular carcinoma after treatment: A protocol for systematic review and meta analysis.磁共振弹性成像测量治疗后肝细胞癌早期复发的肝硬度：系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 Jun 11;100(23):e26183. doi: 10.1097/MD.0000000000026183.
4
Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review.中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值作为不同治疗方式下肝细胞癌患者预后预测指标的Meta分析与系统评价
Cell Physiol Biochem. 2017;44(3):967-981. doi: 10.1159/000485396. Epub 2017 Nov 27.
5
Prognostic significance of long noncoding RNA HOTAIR in hepatocellular carcinoma: A protocol for systematic review and meta-analysis.长链非编码 RNA HOTAIR 在肝细胞癌中的预后意义：系统评价和荟萃分析方案。
Medicine (Baltimore). 2022 Jul 29;101(30):e29406. doi: 10.1097/MD.0000000000029406.
6
Prognostic significance of regulatory T lymphocytes in patients with hepatocellular carcinoma.调节性T淋巴细胞在肝细胞癌患者中的预后意义
J Zhejiang Univ Sci B. 2016;17(12):984-991. doi: 10.1631/jzus.B1600264.
7
The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: A systematic review and meta-analysis.术前中性粒细胞与淋巴细胞比值对接受肝切除术的肝细胞癌患者的预后意义：系统评价和荟萃分析。
Int J Surg. 2018 Jul;55:73-80. doi: 10.1016/j.ijsu.2018.05.022. Epub 2018 May 19.
8
An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.一项评估索拉非尼对晚期肝细胞癌疗效的随机对照试验的最新荟萃分析。
PLoS One. 2014 Dec 2;9(12):e112530. doi: 10.1371/journal.pone.0112530. eCollection 2014.
9
Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.系统评价肝动脉灌注化疗与索拉非尼治疗合并门静脉癌栓的肝细胞癌患者的疗效。
J Gastroenterol Hepatol. 2020 Aug;35(8):1277-1287. doi: 10.1111/jgh.15010. Epub 2020 Mar 3.
10
Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma.肝内白细胞介素-17+ T细胞与叉头框蛋白3+调节性T细胞协同作用促进肝细胞癌的发展并影响其预后。
J Gastroenterol Hepatol. 2014 Apr;29(4):851-9. doi: 10.1111/jgh.12418.

引用本文的文献

1
The Role of Tregs in the Tumor Microenvironment.调节性T细胞在肿瘤微环境中的作用。
Biomedicines. 2025 May 11;13(5):1173. doi: 10.3390/biomedicines13051173.
2
Immunosuppressive CD29 Treg accumulation in the liver in mice on checkpoint inhibitor therapy.在接受检查点抑制剂治疗的小鼠肝脏中，免疫抑制性 CD29 Treg 细胞聚集。
Gut. 2024 Feb 23;73(3):509-520. doi: 10.1136/gutjnl-2023-330024.
3
G Protein-Coupled Receptor Kinase 4 Is a Novel Prognostic Factor in Hepatocellular Carcinoma.G 蛋白偶联受体激酶 4 是肝细胞癌的一个新的预后因素。

本文引用的文献

1
Prognostic role of immune cells in hepatocellular carcinoma.免疫细胞在肝细胞癌中的预后作用。
EXCLI J. 2020 Jun 3;19:718-733. doi: 10.17179/excli2020-1455. eCollection 2020.
2
Immunotherapy for hepatocellular carcinoma.肝细胞癌的免疫治疗。
Cancer Lett. 2020 Feb 1;470:8-17. doi: 10.1016/j.canlet.2019.12.002. Epub 2019 Dec 4.
3
Immunotherapy for hepatocellular carcinoma: Current and future.肝细胞癌的免疫治疗：现状与未来。
Dis Markers. 2022 Jun 20;2022:2628879. doi: 10.1155/2022/2628879. eCollection 2022.
World J Gastroenterol. 2019 Jun 28;25(24):2977-2989. doi: 10.3748/wjg.v25.i24.2977.
4
Hepatocellular Carcinoma.肝细胞癌
N Engl J Med. 2019 Jul 4;381(1):e2. doi: 10.1056/NEJMc1906565.
5
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.MET 抑制剂通过稳定 PD-L1 促进肝脏肿瘤逃避免疫反应。
Gastroenterology. 2019 May;156(6):1849-1861.e13. doi: 10.1053/j.gastro.2019.01.252. Epub 2019 Jan 31.
6
Comprehensive molecular and immunological characterization of hepatocellular carcinoma.全面的肝癌分子和免疫特征分析。
EBioMedicine. 2019 Feb;40:457-470. doi: 10.1016/j.ebiom.2018.12.058. Epub 2018 Dec 29.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody.新型鼠抗人 PD-1 单克隆抗体检测肝癌组织中 PD-1 的表达及临床意义
Int J Oncol. 2018 Jun;52(6):2079-2092. doi: 10.3892/ijo.2018.4358. Epub 2018 Apr 4.
9
Hepatocellular carcinoma.肝细胞癌。
Lancet. 2018 Mar 31;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2. Epub 2018 Jan 5.
10
The evolving concept of liver cancer stem cells.肝癌干细胞的演变概念。
Mol Cancer. 2017 Jan 30;16(1):4. doi: 10.1186/s12943-016-0572-9.